FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.
Jessica Roberts, PharmD, RPh
Advertisement
Articles by Jessica Roberts, PharmD, RPh
New oral GLP-1 agonist orforglipron cuts A1C and drives meaningful weight loss in trials, offering easier dosing than injections.
Advertisement
Latest Updated Articles
Elinzanetant: Advancing Treatment for Vasomotor SymptomsMarch 3rd 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5